COMPASS Pathways Plc American Depository Shares (CMPS) vs Structure Therapeutics (GPCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
COMPASS Pathways Plc American Depository Shares (CMPS) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 55.7% versus a loss of 53.0%. Structure Therapeutics is the larger company by market cap ($1.15 billion vs $1.14 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPS | GPCR |
|---|---|---|
| Share price | $8.05 | $16.13 |
| Market cap | $1.14B | $1.15B |
| 1-day change | -6.94% | -5.78% |
| YTD return | +16.67% | -76.81% |
| 1-year return | +55.71% | -53.00% |
| 5-year return | -75.42% | — |
| EPS (TTM) | $-2.34 | $-3.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-287.86M | $-141.20M |
| 52-week high | $15.87 | $94.90 |
| 52-week low | $4.88 | $16.06 |
| Distance from 52-week high | -49.28% | -83.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +189.57% | +550.09% |
| Average volume | 3.09M | 1.18M |
| Shares outstanding | 141.71M | 71.59M |
| Employees | 156 | 281 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CMPS has outperformed GPCR by 108.7 percentage points over the past year.
About COMPASS Pathways Plc American Depository Shares
CMPS stock →COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 156 employees
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
CMPS vs GPCR FAQ
Which is bigger, COMPASS Pathways Plc American Depository Shares or Structure Therapeutics?
Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.15B compared with $1.14B for COMPASS Pathways Plc American Depository Shares (CMPS).
Which stock has performed better over the past year, CMPS or GPCR?
CMPS returned +55.71% over the past 12 months, compared with -53.00% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are COMPASS Pathways Plc American Depository Shares and Structure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.